Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 20/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12168753 | 0.87 | NR1H4 (0.46) | NR1H4 | |
| SCHEMBL20943968 | 0.87 | NR1H4 (0.46) | NR1H4 | |
| SCHEMBL2004979 | 0.87 | NR1H4 (0.48) | NR1H4 | |
| SCHEMBL12168749 | 0.85 | NR1H4 (0.55) | NR1H4 | |
| SCHEMBL20859046 | 0.85 | NR1H4 (0.45) | NR1H4 | |
| SCHEMBL21912422 | 0.83 | NR1H4 (0.52) | NR1H4 | |
| SCHEMBL21340402 | 0.83 | NR1H4 (0.44) | NR1H4 | |
| SCHEMBL19689533 | 0.83 | NR1H4 (0.44) | NR1H4 | |
| SCHEMBL12629327 | 0.82 | NR1H4 (0.46) | NR1H4 | |
| SCHEMBL12168750 | 0.82 | NR1H4 (0.40) | NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055094-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-12358903-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| US-20220242858-A1 | FXR (NR1H4) MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2022-08-04 | — | — | US | disclosed |
| US-11339147-B2 | Lactam compound as FXR receptor agonist | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2022-05-24 | — | — | US | disclosed |
| EP-3730487-B1 | AZETIDINE DERIVATIVES AS FXR (NR1H4) MODULATORS | GILEAD SCIENCES INC (US) | 2022-04-27 | — | — | EP | disclosed |
| EP-3730487-B1 | AZETIDINE DERIVATIVES AS FXR (NR1H4) MODULATORS | GILEAD SCIENCES INC (US) | 2022-04-27 | — | — | EP | disclosed |
| US-11247986-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-11247986-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| CN-108430998-B | Azabicyclo derivatives, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2021-07-09 | — | — | CN | disclosed |
| CN-108064223-B | FXR (NR1H4) MODULATING COMPOUNDS CONTAINING HYDROXY GROUPS | 吉利德科学公司 | 2021-06-01 | — | — | CN | disclosed |
| WO-2016096116-A1 | NOVEL FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016096115-A1 | HYDROXY CONTAINING FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016096116-A1 | NOVEL FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| US-8952042-B2 | FXR (NR1H4) binding and activity modulating compounds | PHENEX PHARMACEUTICALS AG (DE) | 2015-02-10 | — | — | US | disclosed |
| US-8952042-B2 | FXR (NR1H4) binding and activity modulating compounds | PHENEX PHARMACEUTICALS AG (DE) | 2015-02-10 | — | — | US | disclosed |
| EP-2467366-B1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2014-11-12 | — | — | EP | disclosed |
| US-20120232116-A1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2012-09-13 | — | — | US | disclosed |
| US-20120232116-A1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2012-09-13 | — | — | US | disclosed |
| EP-2289883-A1 | Novel FXR (NR1H4) binding and activity modulating compounds | Phenex Pharmaceuticals AG (DE) | 2011-03-02 | — | — | EP | disclosed |
| WO-2011020615-A1 | NOVEL FXR (NR1H4 ) BINDING AND ACTIVITY MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358903-B2 | FXR (NR1H4) modulating compounds | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885 |
| US-11247986-B2 | FXR (NR1H4) modulating compounds | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885 |
| US-20120232116-A1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885 |
| US-11339147-B2 | Lactam compound as FXR receptor agonist | NR1H4, GPBAR1, SLC10A1 | NR1H4 1/4885 |
| US-20220242858-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885 |
| US-20260055094-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.